GSK (FKA Glaxosmithkline INC.)

Based in DC

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $39.9M in lobbying spend across 35 quarterly filings, GSK (FKA Glaxosmithkline INC.) is one of the biggest lobbying spenders in Washington. They deploy 16 individual lobbyists Their lobbying covers 5 issue areas. Active from 2018 to 2025.

$39.9M
Total Spend
8
Years Active
1
Firms Hired
16
Lobbyists Deployed
5
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$4.6M
2019$4.4M
2020$3.8M
2021$6.3M
2022$5.3M
2023$5.1M
2024$4.8M
2025$5.6M

Issues Lobbied

Health IssuesTradeCopyright/PatentMedicare/MedicaidBudget/Appropriations

Lobbying Firms

GSK (FKA Glaxosmithkline INC.)

Lobbyists

Kimberly WilliamsWilliam SchuylerJonathan CauseyMichael CalvoPhilip ThevenetShira KilcoyneAlec HinojosaJennifer DaleCurtis RhyneElizabeth BrewerAmy EfantisJonathan MartinezMonica CloudLiam MacdonaldHarmeet DhillonBrenton Fisk

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Trade, Copyright/Patent, Medicare/Medicaid, Budget/Appropriations

  • •H.R. 449: Synthetic Drug Awareness Act: Provisions related to synthetic drug report
  • •H.R. 749: Lower Drug Costs through Competition Act - Provisions related to generic drug approvals
  • •H.R. 878: Right to
  • •Trade Agreements and related policy issues
  • •Biopharmaceutical innovation policy issues
  • •International intellectual property and market access policy issues
  • •Pricing and reimbursement policy issues
  • •Canada
  • •H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements
  • •H.R. 5340: The Support Technology & Research for Our Nati
  • •H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation
  • •H.R. 849: Protecting Seniors Access to Medicare Act - Provisions related
  • •H.R. 195: Making further continuing appropriation for the fiscal year ending September 30, 2018, and for other purposes.
  • •H.R. 1625: Consolidated Appropriations Act, 2018
  • •H.R. 1892: Bipartisan Budget A

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders
🏭 Tech Lobbying
Industry overview and top spenders

Related Investigations

Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
The 22,000% ROI
When lobbying spending yields outsized returns.

Similar Clients

Siemens Healthineers (FKA Varian Medical Systems, INC.)
$1.9M total spend
Grifols Shared Services North America INC
$8.1M total spend
The Campaign for Sustainable Rx Pricing
$2.6M total spend
Alliance for Retired Americans
$2.5M total spend
Biotechnology Innovation Organization (Formerly Biotechnology Industry Org.)
$2.2M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.